Skip to main content
. 2021 Jul 31;10(8):972. doi: 10.3390/pathogens10080972

Table 2.

AGREE II domain scores for the 12 guidelines, after a blind evaluation by two appraisers.

Guidelines Scope and Purpose Stakeholder Involvement Rigor of Development Clarity of Presentation Applicability Editorial Independence Overall Assessment Recommended
ILADS [27] 100% 69% 58% 22% 31% 13% 42% N
PSEID [20] 81% 31% 10% 58% 44% 29% 33% N
SSID and SSN [17] 100% 58% 89% 67% 81% 67% 83% Y
BAPCOC [26] 72% 50% 40% 67% 71% 58% 53% YM
AWMF [24] 100% 100% 96% 86% 81% 100% 100% Y
ESGBOR [18] 75% 58% 66% 42% 44% 79% 50% YM
HAS [22] 100% 100% 88% 83% 79% 54% 75% YM
NICE [23] 100% 100% 94% 89% 100% 100% 100% Y
AWMF [25] 100% 100% 98% 89% 94% 100% 100% Y
French scientific societies [7] 100% 100% 99% 87% 92% 100% 100% Y
Canada [21] 64% 36% 17% 39% 85% 42% 25% N
IDSA [19] 100% 100% 100% 63% 94% 96% 100% Y
Median ± IQR 100% ± 22% 85% ± 46% 88% ± 48% 67% ± 35% 81% ± 36% 73% ± 52% 79% ± 54%
Cohen’s kappa - - - - - - 0.90 (0.84–0.96)

Y = yes, YM = yes with modifications, N = no, ILADS = International Lyme and Associated Diseases Society; PSEID = the Polish Society of Epidemiology and Infectious diseases, SSID = Swiss Society of Infectious Disease, SSN = Swiss Society of Neurology; BAPCOC = Belgian Antibiotic Policy Coordination Committee; AWMF = The Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften; ESGBOR = European Study Group for Lyme Borreliosis; HAS = Haute Autorité de Santé, High Health Authority; NICE = National Institute for Health and Care Excellence; IDSA = Infectious Diseases Society of America.